Patent Picks—Melanin Stimulator, Broad-spectrum Antioxidant, AHA Boost to BHA Solubility and More

Patent Picks are taken from publicly available sources and cover recent patent applications or issuances in the cosmetic, personal care and peripheral markets. This edition features technologies related to skin care actives.

Photosensitizers for acne, rosacea and hair removal
US Patent 8492578
Publication date: July 23, 2013
Assignee: Photoderma SA

This invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. ALA (5-aminolevulinic acid)-esters of body-owned, natural compounds such as amino acids, steroids, carbohydrates and alcohols are preferred examples. These compounds are designed for topical application and characterized by low permeability to the stratum corneum and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties for the skin without causing damage, as prior art compounds do. Applications include treatment of psoriasis, sebaceous glands and related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer and precancer, as well as in cosmetic hair removal.

Wound-healing, reparative azetidine derivatives
US Patent 8492561
Publication date: July 23, 2013
Assignee: Allergan, Inc.

Described by this patent are novel azetidine derivatives and their use as modulators of sphingosine-1-phosphate receptors. In relation to personal care, applications include: scar-free wound healing, and prevention and treatment of photoaging and skin aging.

Melanocortin-1-stimulating cyclic peptides
US Patent 8492517
Publication date: July 23, 2013
Assignee: Palatin Technologies, Inc.

Melanocortin receptor-specific cyclic peptides and their formulation are disclosed in this patent and further directed toward the treatment of dermatologic and cosmetic diseases and conditions. In one aspect, these peptides are used to stimulate melanocytes and related cells to increase the level of melanin in the skin. Increasing the level of melanin in the skin in turn provides protection against ultraviolet radiation (UVR) and sunlight, including protection against phototoxicity and photosensitivity.

Histone hyperacetylating agents for treatment of rosacea, erythema, blemishes and other skin conditions
US Patent 8492438
Publication date: July 23, 2013
Assignee: Asan Laboratories Company (Cayman), Ltd.

Derscribed herein are compositions including a histone hyperacetylating agent or a pharmaceutically acceptable salt thereof, and methods for treating skin disorders including rosacea, pityriasis rosea, erythema, rhinophyma and rosacea-associated disorders including pimples, papules, pustules and telangiectasia. The related preparations may be creams, ointments, gels, sprays, lotions, skin tonics, shampoos or mousses. Specifically, the short-chain fatty acid derivative active is preferably present at a concentration of 0.00001% to 100.00% w/w, or in a dosage of 1 to 1000 mg.

A skin care composition for rejuvenating skin according to the present invention may comprise further ingredients: petrolatum, waxes, lanolin, silicone, liposomes, vegetable, mineral oils, plasticizers, fragrances, preservatives, a penetration enhancing agent, a pH adjusting agent or other suitable ingredients for topical skin compositions. Such ingredients can moisturize skin, stabilize the active compound, increase drug-skin contact and local concentration, control drug slow release, and/or aid in decreasing skin erythema and breakage, preventing skin atrophy, fibrosis and infection, and promoting skin wound healing.

Topical thiazolidine derivatives for broad-spectrum anti-oxidative effects
US Patent 8492417
Publication date: July 23, 2013
Assignee: Exsymol S.A.M.

The inventors on this patent aim to address the destructive effects of oxidative stress and its toxic by-products in skin by administering a topical formula incorporating thiazolidine heterocyclic derivatives; in particular, 2-oxo-1,3-thiazolidine. These materials are reportedly efficient against the largest possible panel of reactive oxygen species, possessing broad spectrum “anti-stress” properties. They also present favorable cutaneous penetration in order to reach different cutaneous tissue sites, and are resistant to hydrolytic skin systems, and thus skin metabolization. Lastly, their interaction with ROS produces no toxic by-products.

Thiazolopyridine sirtuin-modulating compounds for anti-aging, anti-inflammation and more
US Patent 8492401
Publication date: July 23, 2013
Assignee: GlaxoSmithKline LLC

Described herein are sirtuin-modulating compounds that are used to increase the lifespan of cells and treat and/or prevent a wide variety of diseases and disorders; for example, disorders related to aging or stress, inflammation, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Skin is contacted with a pharmaceutical or cosmetic composition comprising a sirtuin-modulating compound, which increases the level and/or activity of a sirtuin protein and can address inflammation, sun damage, natural aging or wound healing.

AHA boost to BHA solubility for stronger skin peels
US Patent 8492366
Publication date: July 23, 2013
Assignee: Societe L'Oreal S.A.

According to this patent, the solubility in alcoholic media of beta-hydroxy acids (BHAs) such as salicylic acid is markedly enhanced in the presence of at least one alpha-hydroxy acid (AHA). The present invention thus features higher potency, more concentrated BHA skin peel cosmetic/dermatological compositions, as well as a chemical skin peel regimen including same.

Degradable, size-controlled nanoparticles for delivery
US Patent 8492510
Publication date: July 23, 2013
Assignee: Vanderbilt University

This invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles and functionalized nanoparticles and methods of making and using same. In one aspect, degradable polymer and nanoparticles are specified, as are methods of controlling particle size during the preparation of them. Applications include complexing, delivering and releasing payloads such as actives.

More in Literature/Data